Cardiovascular and Renal Drugs Advisory Committee Meeting

Hilton Washington DC/Silver Spring, The Ballrooms 8727 Colesville, Road, Silver Spring, Maryland

September 20, 2010

Meeting Roster

CARDIOVASCULAR AND RENAL DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Sanjay Kaul, M.D. Darren McGuire, M.D., MHSc

Director, Fellowship Training Program in Associate Professor

Cardiovascular Diseases University of Texas Southwestern Cedars-Sinai Heart Institute Medical Center, Cardiology

Professor, David Geffen School of Medicine at UCLA Dallas, Texas

Division of Cardiology Cedar Sinai Medical Center Los Angeles, California

Mori J. Krantz, M.D., F.A.C.C., F.A.C.P.

James D. Neaton, Ph.D. Associate Professor Professor of Biostatistics University of Colorado Division of Biostatistics Denver Health, Cardiology Coordinating Centers for Biometric Research

Director, CV Prevention, & ECG Core Lab University of Minnesota School of Public Health

Minneapolis, Minnesota Colorado Prevention Center, Community Health Denver, Colorado

INDUSTRY REPRESENTATIVE (Non-Voting)

Jonathan C. Fox, M.D., Ph.D., F.A.C.C.

Vice President, Clinical Therapeutic Area Cardiovascular and Gastrointestinal Diseases Research & Development, Clinical Development

AstraZeneca LP Wilmington, Delaware

TEMPORARY MEMBERS (Voting)

Allan Coukell, Bsc. Pharm.

(Acting Consumer Representative) Director, Medical Safety Portfolio

Pew Health Group

The Pew Charitable Trusts

Washington, District of Columbia

Scott Emerson, M.D., Ph.D.

Professor of Biostatistics Department of Biostatistics University of Washington Seattle, Washington

A. Michael Lincoff, M.D. (Acting Chair)

Vice Chairman, Department of Cardiovascular Medicine

Director, C5Research (Cleveland Clinic Coordinating

Center for Clinical Research)

Professor of Medicine

Cleveland Clinic

Cleveland, Ohio

Steven Nissen, M.D., MACC

Professor of Medicine

Cleveland Clinic Lerner School of Medicine

at Case Western Reserve University

Chairman, Department of Cardiovascular Medicine

Cleveland Clinic Foundation

Cleveland, Ohio

<u>Tom Simon</u> (Patient Representative)

Director, Interfaith Companion And Ride Express

Inc. (I CARE) Decatur, Georgia

Cardiovascular and Renal Drugs Advisory Committee Meeting

Hilton Washington DC/Silver Spring, The Ballrooms

8727 Colesville Road, Silver Spring, Maryland

September 20, 2010

Meeting Roster

FDA PARTICIPANTS (Non-Voting)

Robert Temple, M.D.

Director of the Office of Medical Policy Director, Office of Drug Evaluation (ODE) I Center for Drug Evaluation and Research (CDER) Food and Drug Administration (FDA)

Ellis F. Unger, M.D.

Deputy Director, Division of Cardiovascular and Renal Drug Products (DCRP), ODE I, CDER, FDA

Norman Stockbridge, M.D.

Director, Division of Cardiovascular and Renal Drug Products (DCRP), ODE I, CDER, FDA